GBIM
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2016 Q1 | -0.15 | $942,750 | -$1M |
| 2015 Q4 | -0.14 | $1M | -$1M |
| 2015 Q3 | 0.16 | $3M | -$1M |
| 2015 Q2 | -0.23 | $1M | -$2M |
| 2015 Q1 | -0.27 | $1M | -$2M |
| 2014 Q4 | -0.30 | $2M | -$2M |
| 2014 Q3 | -1.13 | $1M | -$2M |
| 2014 Q2 | -1.04 | $2M | -$3M |